{"name":"Laboratoires NEGMA","slug":"laboratoires-negma","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ART 44","genericName":"ART 44","slug":"art-44","indication":"Treatment of HIV-1 infection in adults and children","status":"phase_3"},{"name":"ART 50","genericName":"ART 50","slug":"art-50","indication":"Treatment of HIV-1 infection in adults and children","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Diacerhein","genericName":"Diacerhein","slug":"diacerhein","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"ART 44","genericName":"ART 44","slug":"art-44","phase":"phase_3","mechanism":"ART 44 is an antiretroviral drug used to treat HIV-1 infection.","indications":["Treatment of HIV-1 infection in adults and children","Prevention of mother-to-child transmission of HIV-1"],"catalyst":""},{"name":"ART 50","genericName":"ART 50","slug":"art-50","phase":"phase_3","mechanism":"ART 50 is an antiretroviral medication used to treat HIV-1 infection.","indications":["Treatment of HIV-1 infection in adults and children","Prevention of mother-to-child transmission of HIV-1"],"catalyst":""},{"name":"Diacerhein","genericName":"Diacerhein","slug":"diacerhein","phase":"marketed","mechanism":"Caspase-3, Caspase-7, N-acylethanolamine-hydrolyzing acid amidase","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNd1NMR01HVWJ2Rk5PVE42MnloMUswa0hZZDg2ZkZSUTZKMXRBbmZxc2RLbnVpQWxFWnRxVWxUOEExQUxHdmJPY0tXdzZpZHlXQVpRb21VdTY1bWZaRDhpTXJZeTgxdVJVLTFYc2Nvb01JTTh6WnpHd3VCVDlKVUtVRzdCenJwaHczOU1FVWJkb1dqLWRkX3NCZVJyTWFNNE5fdzNoWEViTFF4OVYxV2hOZmdTUFYtZ0Yz?oc=5","date":"2025-10-30","type":"pipeline","source":"Wolters Kluwer","summary":"Imminent Infringement: The UPC’s New Geography of Pharmaceutical Risk - Wolters Kluwer","headline":"Imminent Infringement: The UPC’s New Geography of Pharmaceutical Risk","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":2,"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}